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Abstract 
Introduction: The development of bipolar resection using saline irrigation provided significant improvements in NMIBT 
treatment. The aim of our study was to evaluate the efficacy and safety of a newly introduced endoscopic technique, the bipolar 
transurethral resection in saline – plasma vaporization of bladder tumors (TURis-PVBT). 
Materials and Methods: Between May and October 2009, 57 consecutive patients presenting papillary bladder tumors larger 
than 1 cm underwent TURis-PVBT and a 3 months follow-up. Initial tumor biopsy, followed by plasma vaporization of the tumor and 
biopsies of the tumoral bed were performed in all cases. Complementary treatment was applied according to risk indications. The 
follow-up protocol included abdominal ultrasonography, cytology and cystoscopy at 3 months. 
Results: TURis-PVBT was successfully performed in all cases. Multiple tumors were found in 45.6% of the cases and 50.9% 
of the patients presented tumors larger than 3 cm. The mean tumoral volume was of 11 ml. The mean operative time was of 17 
minutes, the mean hemoglobin decrease was of 0.4 g/dl, the mean catheterization period was of 2.5 days and the mean hospital 
stay was of 3.5 days. The pathological exam diagnosed 57.9% pTa cases, 31.6% pT1 cases and 10.5% pT2 cases. No tumoral base 
biopsies were positive for malignancy. The recurrence rate at 3 months for the 51 NMIBT patients was of 15.7%. Orthotopic 
recurrent tumors were encountered in 5.9% of the cases. 
Conclusions: TURis-PVBT seems to represent a promising endoscopic treatment alternative for NMIBT patients, with good 
efficacy, reduced morbidity, fast postoperative recovery and satisfactory follow-up parameters. 
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Introduction
The endoscopic treatment of NMIBT patients 
represented a challenge for the urologist since the very 
beginning. From the first resectoscope invented by Stern 
in New York in 1926 [1] to the modern instruments using 
bipolar energy, TURBT faced many shortcomings, as well 
as a significant rate of intra- and postoperative 
complications. 
According to the EAU Guidelines 2009, TURBT 
aiming to achieve complete macroscopic eradication 
including a part of the underlying muscle represents the 
standard therapy for Ta and T1 papillary bladder tumors. 
The goal of TURBT is to make the correct diagnosis and 
to remove all the visible lesions [2]. 
However, bladder tumors characterized by specific 
features, such as their location in places that are difficult 
to be accessed (bladder dome, anterior bladder wall) or 
subject to obturator nerve stimulation (lateral bladder 
walls), as well as their size (larger than 3 cm), imposed 
the search for improvement in endoscopic surgical 
approach.  
On the other hand, the significant complications of 
standard monopolar resection, consisting of bladder wall 
perforation, intra- and postoperative bleeding (eventually 
imposing blood transfusions or reintervention), urinary 
retention by blood clots, obturator nerve stimulation, 
tumoral spilling and urethral strictures also demanded the 
search for new alternatives. 
The bipolar transurethral resection in saline (TURis) 
proved to offer the patients the same results as monopolar 
technology, thus guaranteeing maximum safety without 
increasing the incidence of urethral strictures [3]. 
TURis plasma vaporization was recently introduced 
in the armamentarium treatment for benign prostatic 
hyperplasia (BPH) and described as a safe and effective 
treatment option for patients with low urinary tract 
symptoms due to bladder outlet obstruction [4]. 
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Following the tradition of promoting new techniques 
in endourology, the Department of Urology of “St. John” 
Clinical Emergency Hospital introduced TURis plasma 
vaporization as an absolute national premiere in Romania, 
in May 2009.  
It was initially performed for BPH patients, but as 
soon as we realized the potential benefits of tumoral 
tissue plasma vaporization, we started applying this 
technique to papillary bladder tumors as well. With this 
regard, we may proudly state that the Romanian 
experience of “St. John” Department of Urology is among 
the very few existing at this moment, in the world. 
In this study, we aimed at evaluating the efficiency, 
safety and short-term postoperative results of this new 
endoscopic technique. 
Materials and Methods 
Between May and October 2009, 57 consecutive 
patients with papillary bladder tumors underwent  
 
TURis-PVBT and a 3 months follow-up.  
The Olympus SurgMaster UES-40 bipolar 
generator, the special “mushroom” type vapo-resection 
electrode and the continuous saline flow irrigation were 
used in all cases. 
All patients underwent a standard investigation 
protocol, which included general clinical examination, 
blood tests, urine culture, abdominal ultrasonography, 
intravenous pyelography and eventually CT-scan.  
All the procedures were carried out under spinal 
anesthesia by a single surgeon. Plasma vaporization was 
performed only for papillary tumors larger than 1 cm in 
diameter.  
The procedure started with a comprehensive 
cystoscopy, determining the presence, size and location of 
all existing tumors (Fig. 1). 
The next step consisted of bipolar resection of 
several tumoral tissue specimens for the pathological 
analysis (Fig. 2), and was followed by the actual plasma 
vaporization (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 – Large bladder tumors before plasma vaporization 
Fig. 2 – Bipolar resection of several tumoral tissue specimens 
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Fig. 3 – Initial aspects at the beginning of TURis-PVBT 
 
The spherical shaped new type of electrode 
displaying a plasma corona on its surface was gradually 
moved in direct contact with the tumoral tissue (the 
“hovering” technique), thus producing a virtually blood-less 
vaporization at 280 W (Fig. 4).  
 
Coagulation of any hemorrhagic sources was practically 
concomitant, while larger vessels’ hemostasis was achieved by 
reducing the power of the generator to 120-140 W. 
Tumor vaporization enabled the surgeon to clearly 
visualize the muscular layer of the bladder wall (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 – Tumor vaporization by the plasma corona on the surface of the “mushroom” type electrode 
Fig. 5 – Postoperative images showing the clean muscular layer of the bladder wall   
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Consequently, bipolar resection of the center and 
margins of the tumoral bed was performed for the 
pathological confirmation of the complete tumor removal  
 
(Fig. 6). The coagulation of the tumoral bed and margins 
of the resection area also using the “mushroom” electrode, 
took place at the end of the procedure (Fig. 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 – Bipolar resection of the center and margins of the tumoral bed 
Fig. 7 – Coagulation of the tumoral bed and margins of the resection area 
 
 
A single mitomycin-C instillation was performed 
during the first 6 hours after the procedure in all cases. A 
complementary intravesical treatment consisting of 
mitomycin-C or BCG instillations was applied in NMIBT 
patients according to their risk group. The muscle-invasive 
bladder cancer cases were excluded from the study and 
scheduled for radical cystectomy.  
The follow-up was performed 3 months after surgery 
for all NMIBT cases. The follow-up protocol included 
abdominal ultrasonography, urinary cytology and 
cystoscopy. 
Results 
TURis-PVBT was successfully performed in all 
cases. The mean patients’ age was of 61 years old 
(between 36 and 85 years old). The mean tumoral volume 
was of 11 ml (between 4 and 35 ml). The proportions of 
cases presenting solitary tumors smaller and respectively 
larger than 3 cm were of 21.1% and 33.3%, while for 
multiple tumors, these percentages were of 28.1% and 
17.5%, respectively.  
Consequently, tumors larger than 3 cm were 
encountered in 50.9% of the cases and multiple tumors 
were found in 45.6% of the patients. Recurrent bladder 
cancer was diagnosed in 22.8% of the patients, while 
77.2% of the cases presented primary tumors. 
The mean operative time was of 17 minutes 
(ranging from 6 to 35 minutes) and the mean 
postoperative hemoglobin decrease was of 0.4 g/dl 
(ranging from 0.2 and 0.9 g/dl). An immediate 
postoperative instillation of mytomicin C was applied in all 
patients. 
The mean catheterization period was of 2.5 days 
(between 2 and 3.5 days) and the mean hospital stay was 
of 3.5 days (between 2.5 and 4.5 days).  
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Initial tumoral biopsy, followed by plasma 
vaporization of the tumor and biopsy of the tumoral bed 
were successfully completed for every patient. 
We encountered no case of bladder wall perforation, 
persistent intraoperative bleeding or postoperative urinary 
retention by blood clots. None of the patients required 
blood transfusion or reintervention. There was a single 
case of obturator nerve stimulation (1.7%) and another 
(1.7%) of prolonged postoperative mild hematuria, 
successfully treated with conservative means.  
The pathological exam diagnosed 57.9% pTa cases, 
31.6% pT1 cases and 10.5% pT2 cases. All resected 
specimens were valid for pathological analysis. No 
tumoral base biopsies were positive for malignancy and 
they included muscular fibers in all cases. The six muscle-
invasive bladder cancer cases underwent radical 
cystectomy. 
The recurrence rate at 3 months for the 51 NMIBT 
patients was of 15.7%. In this series, 21.6% of the patients 
initially had single tumors smaller than 3 cm, 33.3% single 
tumors larger than 3 cm, 27.5% multiple tumors smaller 
than 3 cm and 17.6% multiple tumors larger than 3 cm).  
Orthotopic recurrences alone were encountered in 
3.9% of the cases, 9.8% of the patients only had 
heterotopic tumors and 2% (1 patient) had both ortho- and 
heterotopic recurrences. The recurrence rate was of 9.1% 
for patients with initial single tumor smaller than 3 cm and 
of 17.5% in cases of single tumors larger than 3 cm or of 
multiple tumors.  
Discussion  
TURi-PVBT is a new procedure, at the very 
beginning as part of the treatment armamentarium for 
non-muscle invasive bladder cancer. While gaining an 
increasing acknowledgement as a reliable therapeutic 
alternative for BPH [4], the use of this method in NMIBT 
patients has not yet been evaluated in clinical trials. 
Therefore, one of the most important features of the 
present study is related to its pioneering character. 
From the technical point of view, TURis-PVBT 
ensured a high quality tumor ablation with excellent 
visibility due to minimal bleeding. The advantages of the 
procedure mainly consisted of: reduced stimulation of the 
obturator nerve, lack of bladder perforation and virtually no 
major postoperative bleeding. 
Subjectively, this type of vaporization did not alter 
the visual characteristics of the anatomical layers, 
enabling the surgeon to differentiate between the tumoral 
tissue, the muscular fibers of the bladder wall, as well as 
the clear boundaries of the operating area, with increased 
accuracy. Due to the lack of bleeding, visibility remained 
excellent throughout the procedure. The vaporization area 
emphasized a remarkably smooth surface and sharp 
margins, with no irregularities or debris.  
As some stages of the conventional TURBT were 
significantly reduced (concomitant vaporization and 
hemostasis, rapid evacuation of the few resected tissue 
fragments), the actual vaporization occupied the great 
majority of the operating time and increased the efficiency 
of TURis-PVBT. 
The comparison of this method with the literature 
data seems to confirm the potential advantages provided 
by TURis-PVBT. A study performed by Puppo et al. 
concerning bipolar TURBT, involving a number of 480 
patients with similar parameters and using the same 
TURis generator as the one in our study, determined a 
mean operating time of 27 minutes, an obturator nerve 
stimulation rate of 2%, a mean hemoglobin decrease of 
0.7 g/dl, a transfusion rate of 0.8%, a blood clot retention 
rate of 2% and a mean catheterization period of 3 days 
[3]. 
Although rather small, our series seems to 
emphasize improved results in all regards: a mean 
operative time of 17 minutes, a 1.7% rate of obturator 
nerve stimulation, a mean postoperative hemoglobin 
decrease of 0.4 g/dl, a mean catheterization period of 2.5 
days and no cases of blood transfusion or blood clot 
retention. 
The standard TURBT is still marked by a significant 
number of complications, which new treatment 
alternatives aim to avoid. The extensive study by Collado 
et al. on 2821 patients assessed the most common 
complications related to monopolar TURBT and 
determined a bleeding rate of 2.8%, a perforation rate of 
1.3%, a re-intervention rate of 2.7% and a blood 
transfusion rate of 3.4%. [5]  
The fact that none of these complications occurred 
in our study group can be considered quite promising, as 
TURis-PVBT seems to optimize efficacy and to increase 
safety during the endoscopic approach of bladder tumors. 
The catheterization period was also longer for monopolar 
TURBT (5 days versus 2.5 days in our series). 
An important issue is represented by the difficulties 
concerning the resection of large bladder tumors, which 
many times imply important bleeding rates, prolonged 
resection time, poor visibility as well as an increased rate 
of complications. For example, Collado et al. reported a 
6.7% rate of complications in cases of tumors larger than 
3 cm. [5] 
Maybe one of the most important benefits of TURis-
PVBT is represented by the rapid vaporization of large 
quantities of tumoral tissue with minimal blood loss. We 
were able to successfully treat the 29 cases of this kind 
from our series, without complications. 
On the other hand, the resected specimens were 
sufficient for the pathological analysis and included 
muscular layer for every tumor, so that stage and grading 
were clearly determined in all cases. 
There are various results mentioned in the literature 
data concerning the recurrence rate at the 3 months 
follow-up cystoscopy. A study by Guney et al. on 641 
patients during a period of 10 years determined a 
recurrence rate of 21% at 3 months. [6] On the other 
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hand, the combined analysis of seven EORTC studies 
performed by Brausi et al. on 2410 NMIBT patients 
determined a 3 months recurrence rate of 13.1% [7].  
Consequently, it would only be fair to say that the 
15.7% 3 months recurrence rate in our series appears to 
confirm the fact that TURis-PVBT is a successful 
approach in terms of oncological safety as well, with a 
short-term recurrence rate that matches the one of 
monopolar TURBT.  
According to the same meta-analysis by Brausi et 
al., the rate of orthotopic recurrences was of 8.7%, while 
3.2% of the patients presented heterotopic recurrences 
and 3.7% of the cases were diagnosed with both ortho- 
and heterotopic recurrent tumors during the 3 months 
cystoscopy follow-up. [7]  
In our series, we recorded a 3.9% rate of orthotopic 
recurrences, a 9.8% rate of heterotopic tumors and a 
single case (2%) which had both ortho- and heterotopic 
tumors. The practically inversed proportions of ortho- and 
heterotopic recurrences between the two studies seem to 
suggest the superior rate of initial complete removal of 
bladder tumors achieved by TURis-PVBT. 
In a study published by Divrik et al. with regard to 
short-term recurrences after monopolar TURBT, the 
recurrence rate in patients initially diagnosed with a single 
tumor smaller than 3 cm was of 20%, while in cases of  
 
single tumors larger than 3 cm or of multiple tumors, the 
respective rate was of 37%. [8]  
In our series, these recurrence rates were of 9.1% 
and 17.5%, respectively. Consequently, TURis-PVBT 
appears to display remarkable efficacy in terms of 
oncological results as well in cases of large or multiple 
bladder tumors. 
Conclusions 
We may conclude that TURis-PVBT seems to 
represent a promising endoscopic treatment alternative for 
NMIBT patients, with good efficacy, reduced morbidity, 
fast postoperative recovery and satisfactory follow-up 
parameters by comparison to bipolar as well as to 
standard monopolar TURBT.  
Longer follow-up periods and trials that are more 
extensive will be required in order to establish the long-
term advantages and general viability of the method as a 
therapeutic approach in bladder cancer.  
However, the remarkably efficient tumoral tissue 
vaporization, excellent visibility, reduced intra- and 
postoperative bleeding, short period of catheterization and 
hospital stay, lack of complications and good oncological 
results represent reliable arguments in favor of this new 
procedure. 
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